Micardis vs. Allopurinol: side effect and effectiveness comparison - a phase IV clinical study
We compare the side effects and drug effectiveness of Micardis and Allopurinol. The phase IV clinical study is created by eHealthMe based on reports (from sources including the FDA) of 200,467 people who take Micardis and Allopurinol, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
200,467 people who take Micardis and Allopurinol are studied.
What is Micardis?
Micardis has active ingredients of telmisartan. It is often used in high blood pressure. eHealthMe is studying from 26,644 Micardis users for its effectiveness, alternative drugs and more.
What is Allopurinol?
Allopurinol has active ingredients of allopurinol. It is often used in gout. eHealthMe is studying from 166,595 Allopurinol users for its effectiveness, alternative drugs and more.
Number of reports submitted per year:
Drugs being compared in this study:
- Micardis (telmisartan)
- Allopurinol (allopurinol)
Most common side effects of the drugs, overall:
Most common side effects of the drugs, in long term (1+ years) use:
- not at all: 1.69 %
- somewhat: 11.37 %
- moderate: 36.15 %
- high: 40.27 %
- very high: 10.52 %
- not at all: 2.17 %
- somewhat: 14.74 %
- moderate: 24.54 %
- high: 38.29 %
- very high: 20.26 %
Want to compare Micardis with Allopurinol?Personalize this study to your gender and age (0-99+).
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Kato Y, Mukai Y, Rane A, Inotsume N, Toda T, "The inhibitory effect of telmisartan on the metabolism of arachidonic acid by CYP2C9 and CYP2C8: an in vitro study", Biological and Pharmaceutical Bulletin, 2017 Sep .
- Kim HK, Youm JB, Lee SR, Lim SE, Lee SY, Ko TH, Nilius B, Noh JH, Ko KS, Rhee BD, Kim N, "The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action", Pflügers Archiv-European Journal of Physiology, 2012 Dec .
Alternative drugs to, pros and cons of:
- Micardis (25,619 reports)
- Allopurinol (164,096 reports)
Common Micardis side effects:
- High blood pressure: 1,843 reports
- Dizziness: 1,302 reports
- Hypotension (abnormally low blood pressure): 1,110 reports
- Fatigue (feeling of tiredness): 1,090 reports
- Breathing difficulty: 1,059 reports
- Drug ineffective: 1,028 reports
- Diarrhea: 1,002 reports
Browse all side effects of Micardis:a b c d e f g h i j k l m n o p q r s t u v w x y z
Common Allopurinol side effects:
- Diarrhea: 9,701 reports
- Fatigue (feeling of tiredness): 9,558 reports
- Breathing difficulty: 8,893 reports
- Weakness: 8,160 reports
- Fever: 8,048 reports
- Pneumonia: 7,430 reports
- Thrombocytopenia (decrease of platelets in blood): 7,366 reports
Browse all side effects of Allopurinol:a b c d e f g h i j k l m n o p q r s t u v w x y z
How the study uses the data?
The study is based on telmisartan and allopurinol (the active ingredients of Micardis and Allopurinol, respectively). Other drugs that have the same active ingredients (e.g. generic drugs or brand names) are also considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Dilantin-125 and Parkinson'S Disease - a second ago
- Methyldopa and Blood Bilirubin Increased - 27 seconds ago
- Piroxicam and Musculoskeletal Disorder - a minute ago
- Prednisolone and Diffuse Mesangial Sclerosis - a minute ago
- Avodart and Stent - a minute ago
- Tepezza and Inflammation - a minute ago
- Cardiogenic Shock and Hypokalemia - a minute ago
- Trental and Cerebral Atrophy - a minute ago
- Ipratropium Bromide and Intervertebral Disc Degeneration - a minute ago
- Gilenya and Spinal Osteoarthritis - a minute ago